Killer cell immunoglobulin like receptor gene association with tuberculosis

Human Immunology

Volumn 74, Issue 1, 2013, Pages 85-92

  Pydi, Satya Sudheer ^a   Sunder, Sharada Ramaseri ^a   Venkatasubramanian, Sambasivan ^b   Kovvali, Srinivas ^c   Jonnalagada, Subbanna ^a   Valluri, Vijaya Lakshmi ^a  

^a LEPRA Society   (India)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^c Southern Regional Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1;

ARTICLE; CONTROLLED STUDY; EXTRAPULMONARY TUBERCULOSIS; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR THREE DOMAINS LONG CYTOPLASMIC TAIL 1 GENE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR THREE DOMAINS LONG CYTOPLASMIC TAIL 2 GENE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR THREE DOMAINS LONG CYTOPLASMIC TAIL 3 GENE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR TWO DOMAINS LONG CYTOPLASMIC TAIL 4 GENE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR TWO DOMAINS SHORT CYTOPLASMIC TAIL 1 GENE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR TWO DOMAINS SHORT CYTOPLASMIC TAIL 2 GENE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR TWO DOMAINS SHORT CYTOPLASMIC TAIL 3 GENE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR TWO DOMAINS SHORT CYTOPLASMIC TAIL 4 GENE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR TWO DOMAINS SHORT CYTOPLASMIC TAIL 5 GENE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPING TECHNIQUES; HAPLOTYPES; HLA ANTIGENS; HUMANS; IMMUNITY, INNATE; INDIA; KILLER CELLS, NATURAL; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POLYMORPHISM, GENETIC; RECEPTORS, KIR; RECEPTORS, KIR2DL3; RECEPTORS, KIR3DL1; TUBERCULOSIS, PULMONARY;

EID: 84870939755     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.10.006     Document Type: Article

References (53)

1. Annual Status Report. Revised national TB control programme, TB India 2011. http://www.tbcindia.nic.in/pdfs/RNTCP%20TB%20India%202011.pdf.
2. Parasa V.R.R., Sikhamani R., Raja A. Effect of recombinant cytokines on the expression of natural killer cell receptors from patients with TB or/and HIV infection. PLoS One 2012, 7(6):e37448.
3. Pean P., Nerrienet E., Madec Y., Borand L., Laureillard D., Fernandez M., et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood 2012, 119:3315-3320.
4. Dhiman R., Indramohan M., Barnes P.F., Nayak R.C., Paidipally P., Rao L.V.M., et al. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol 2009, 183:6639-6645.
5. Vankayalapati R., Barnes P.F. Innate and adaptive immune responses to human Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 2009, 89(suppl 1):S77-S80.
6. Vankayalapati R., Wizel B., Weis S.E., et al. The NKp46 receptor contributes to NK cell lysis of mononuclearphagocytes infected with an intracellular bacterium. J Immunol 2002, 168(7):3451-3457.
7. Vankayalapati R., Klucar P., Wizel B., et al. NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen. J Immunol 2004, 172(1):130-137.
8. Roy S., Barnes P.F., Garg A., Wu S., Cosman D., Vankayalapati R. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J Immunol 2008, 180(3):1729-1736.
9. Harel-Bellan A., Quillet A., Marchiol C., DeMars R., Tursz T., Fradelizi D. Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. Proc Natl Acad Sci 1986, 83:5688-5692.
10. Moretta A., Tambussi G., Bottino C.C., et al. A novel surface antigen expressed by a subset of human CD32CD161 natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med 1990, 171:695-714.
11. Carrington M., Martin M.P. The impact of variation at the KIR gene cluster on human disease. Immunobiology of natural killer cell receptors. Curr Top Microbiol 2006, 298:225-257.
12. Hsu K.C., Liu X.R., Selvakumar A., Mickelson E., O'Reilly R.J., Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 2001, 169:5118-5129.
13. Middleton D., Meenagh A., Serrano-Vela J.I., Moscoso J., Arnaiz-Villena A. Different evolution of inhibitory and activating killer immunoglobulin receptors (KIR) in worldwide human populations. Open Immunol J 2008, 1:42-50.
14. Biassoni R., Pessino A., Malaspina A., Cantoni C., Bottino C., Sivori S., et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol 1997, 27:3095-3099.
15. Vales-Gomez M., Reyburn H.T., Erskine R.A., Strominger J. Differential binding to HLA-C of p50-activatig and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci 1998, 95:14326-14331.
16. Bruhns P., Marchetti P., Fridman W.H., Vivier E., Daeron M. Differential roles of N- and C terminal immune receptors tyrosine-based motifs during inhibition of cell activation by natural killer cell inhibitory receptors. J Immunol 1999, 162:3168.
17. Namekawa T., Snyder M.R., Yen J.H., et al. Killer cell activating receptors function as costimulatory molecules on CD41CD28 null T cells clonally expanded in rheumatoid arthritis. J Immunol 2000, 165:1138-1145.
18. Yen J.H., Moore B.E., Nakajima T., et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001, 193:1159-1161.
19. Martin M.P., Gao X., Lee G.H., Nelson G.W., Detels R., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002, 31:429-434.
20. Gendzekhadze K., Norman P.J., Abi-Rached L., Graef T., Moesta A.K., Layrisse Z., et al. Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands. Proc Natl Acad Sci 2009, 106(44):18692-18697.
21. Tajik N., Shah-hosseini A., Mohammadi A., Jafari M., Nasiri M., Radjabzadeh M.F., et al. Susceptibility to pulmonary tuberculosis in Iranian individuals is not affected by compound KIR/HLA genotype. Tiss Ant 2011, 79:90-96.
22. Maertzdorf J., Weiner J., Kaufmann S.H.E. Enabling biomarkers for tuberculosis control. Int J Tuberc Lung Dis 2012, 16(9):1140-1148.
23. Abalos A.T., Eggers, Hogan M., Nielson C.M., Giuliano A.R., Harris R.B., et al. Design and validation of a multiplex specific primer-directed polymerase chain reaction assay for killer-cell immunoglobulin-like receptor genetic profiling. Tiss Ant 2010, 77:143-148.
24. Derek M., Faviel G. The extensive polymorphism of KIR genes. Immunology 2009, 129:8-19.
25. Tajik N., Shahsavar F., Mousavi T., Radjabzadeh M.F. Distribution of KIR genes in the Iranian population. Tiss Ant 2009, 74:22-31.
26. Uhrberg M., Valiante N.M., Shum B.P., et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997, 7:753-763.
27. Gonzalez-Galarza F.F., Christmas S., Middleton D., Jones A.R. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011, 39:D913-D919.
28. Maureen P.M., George N., Jeong-Hee L., Fawnda P., Xiaojiang G., et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002, 169:2818-2822.
29. Levinson R.D., Annabelle A., Okada A.A., Ashouri E., Keino H., Rajalingam R. Killer cell immunoglobulin-like receptor gene-cluster 3DS1-2DL5-2DS1-2DS5 predisposes susceptibility to Vogt-Koyanagi-Harada syndrome in Japanese individuals. Hum Immunol 2010, 71:192-194.
30. Levinson R.D., Du Z., Luo L., Holland G.N., Rao N.A., Reed E.F., et al. KIR and HLA gene combinations in Vogt-Koyanagi-Harada disease. Hum Immunol 2008, 69:349-353.
31. Suzuki Y., Hamamoto Y., Ogasawara Y., Ishikawa K., Yoshikawa Y., Sasazuki T., et al. Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J Invest Dermatol 2004, 122:1133-1136.
32. Rajagopalan S., Long E.O. Understanding how combinations of HLA and KIR genes influence disease. J Exp Med 2005, 201(7):1025-1029.
33. Luszczek W., Manczak M., Cislo M., Nockowski P., Wisniewski A., Jasek M., et al. Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum Immunol 2004, 65:758-766.
34. Nelson G.W., Martin M.P., Gladman D., Wade J., Trowsdale J., Carrington M. Heterozygote advantage in autoimmune disease - hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 2004, 173:4273-4276.
35. Nadia W., Cindy P., Pierre B., Eric L., Vincent V. Association of KIR2DS1 and KIR2DS3 with fatal outcome in Ebola virus infection. Immu Gen 2010, 62:767-771.
36. Marin D., Gabriel I.H., Ahmad S., Foroni L., de Lavallade H., Clark R., et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 2011, 10.1038/leu.2011.18.
37. Bonagura V.R., Du Z., Luo L., Gjertson D., Hantam L.J., DeVoti J., et al. KIR3DS1, KIR2DS1, and KIR2DS5 protect against the development of severe Recurrent Respiratory Papillomatosis (RRP) in HPV-6/11-infected patients. J Allergy Clin Immunol 2009, 123:2. 10.1016/j.jaci.2008.12.620.
38. Momot T., Koch S., Hunzelmann N., Krieg T., Ulbricht K., Schmidt R.E., et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 2004, 50(5):1561-1565.
39. Mahfouz R., Halas H., Hoteit R., Saadeh M., Shamseddeen W., Charafeddine K., et al. Study of KIR genes in Lebanese patients with tuberculosis. Int J Tuberc Lung Dis 2011, 15(12):1688-1691.
40. Méndez A., Granda H., Meenagh A., Contreras S., Zavaleta R., Mendoza M.F., et al. Study of KIR genes in tuberculosis patients. Tiss Ant 2006, 68(5):386-389.
41. Gardiner C.M., Guethlein L.A., Shilling H.G., Pando M., Carr W.H., Rajalingam R., et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 2001, 166:2992-3001.
42. Pando M.J., Gardiner C.M., Gleimer M., McQueen K.L., Parham P. The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol 2003, 171:6640-6649.
43. Martin M.P., Nelson G., Lee J.H., et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002, 169:2818-2822.
44. Wilson M.J., Torkar M., Haude A., Milne S., Jones T., Sheer D., et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci 2000, 97:4778-4783.
45. Smyth M.J., Wallace M.E., Nutt S.L., Yagita H., Godfrey D.I., Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 2005, 201:1973-1985.
46. Wang G., Tschoi M., Spolski R., Lou Y., Ozaki K., Feng C., et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003, 63:9016-9022.
47. Takaki R., Hayakawa Y., Nelson A., Sivakumar P.V., Hughes S., Smyth M.J., et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol 2005, 175:2167-2173.
48. Steven J.B., Alina I.M., Ishani P., Francisco B., John E.C. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8 T cells. J Immunol 2006, 176:1490-1497.
49. Vilches C., Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002, 20:217.
50. Rajalingam R., Krausa P., Shilling H.G., Stein J.B., Balamurugan A., McGinnis M.D., et al. Distinctive KIR and HLA diversity in a panel of North Indian Hindus. Immunogenetics 2002, 53:1009-1019.
51. Raja R., Zeying D., Ashley M., Lihui L., Valampuri J.K., Rajamanickam P., et al. Distinct diversity of KIR genes in three southern Indian populations: comparison with world populations revealed a link between KIR gene content and pre-historic human migrations. Immunogenetics 2008, 60:207-217.
52. Kulkarni S., Single R.M., Martin M.P., Rajalingam R., Badwe R., Joshi N., et al. Comparison of the rapidly evolving KIR locus in Parsis and natives of India. Immunogenetics 2008, 60:121-129.
53. Srivastava R.M., savithri B., Khar A. Activating and inhibitory receptors and their role in Natural Killer cell function. Indian J Biochem Biophys 2003, 40:291-299.